- Home
- PRSU vs TSHA Comparison
PRSU vs TSHA Comparison
Compare PRSU & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSU
- TSHA
- Stock Information
- Founded
- PRSU 1926
- TSHA 2019
- Country
- PRSU United States
- TSHA United States
- Employees
- PRSU N/A
- TSHA N/A
- Industry
- PRSU Business Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- PRSU Consumer Discretionary
- TSHA Health Care
- Exchange
- PRSU Nasdaq
- TSHA Nasdaq
- Market Cap
- PRSU 999.2M
- TSHA 728.4M
- IPO Year
- PRSU N/A
- TSHA 2020
- Fundamental
- Price
- PRSU $37.15
- TSHA $3.00
- Analyst Decision
- PRSU Strong Buy
- TSHA Strong Buy
- Analyst Count
- PRSU 3
- TSHA 7
- Target Price
- PRSU $29.67
- TSHA $8.71
- AVG Volume (30 Days)
- PRSU 347.5K
- TSHA 2.9M
- Earning Date
- PRSU 08-06-2025
- TSHA 08-12-2025
- Dividend Yield
- PRSU N/A
- TSHA N/A
- EPS Growth
- PRSU 1138.43
- TSHA N/A
- EPS
- PRSU 9.98
- TSHA N/A
- Revenue
- PRSU $382,378,000.00
- TSHA $8,098,000.00
- Revenue This Year
- PRSU $14.18
- TSHA N/A
- Revenue Next Year
- PRSU $7.27
- TSHA N/A
- P/E Ratio
- PRSU $4.21
- TSHA N/A
- Revenue Growth
- PRSU 4.63
- TSHA N/A
- 52 Week Low
- PRSU $26.66
- TSHA $1.05
- 52 Week High
- PRSU $47.49
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- PRSU 70.25
- TSHA 63.38
- Support Level
- PRSU $34.35
- TSHA $2.76
- Resistance Level
- PRSU $35.56
- TSHA $3.05
- Average True Range (ATR)
- PRSU 1.41
- TSHA 0.15
- MACD
- PRSU 0.29
- TSHA 0.00
- Stochastic Oscillator
- PRSU 92.21
- TSHA 75.51
About PRSU Pursuit Attractions and Hospitality Inc. Common Stock
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.